Ascentage Pharma Group International (HKG:6855) raised $126.4 million from its US initial public offering of 7,325,000 American depository shares placed to at least six parties at $17.25 apiece, a Tuesday press release said.
The drug maker plans to use the net proceeds of $112.9 million for NDS approval for a drug and its launch in China, for clinical development of Olverembatinib in the United States and other countries, for research and development and for the development of the future pipeline programs of the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。